Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002188
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of ALRT1057 in Patients With AIDS-Related Kaposis Sarcoma
Sponsor:
Anderson Clinical Research
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
1997-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposis sarcoma KS
Detailed Description:
Patients receive open-label ALRT1057 for 16 weeks as tolerated In the absence of unacceptable toxicity patients may continue treatment indefinitely provided they continue to benefit from therapy and the study remains open and active
Thirteen patients are treated initially If at least one response is observed in these patients up to 14 additional patients will be evaluated
Thirteen patients are treated initially If at least one response is observed in these patients up to 14 additional patients will be evaluated
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 96ACR-LIG2 | None | None | None |
| L1057-28 | None | None | None |